Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor (TCR) recognizing Poa compressa-derived peptide–MHC complexes is a membrane-bound protein complex on CD4+ T cells that plays a pivotal role in the allergic response to Canada bluegrass pollen [1]. This TCR specifically identifies allergenic peptides, such as those from the major allergens Poa c 1 and Poa c 5, when they are presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells [1, 2]. The binding of the TCR to these complexes initiates a signaling cascade that drives the differentiation and activation of Th2 cells [3]. These cells then secrete cytokines like IL-4 and IL-13, which stimulate B cells to produce allergen-specific IgE, ultimately leading to the mast cell degranulation and eosinophilic inflammation seen in allergic rhinitis and asthma [3, 4]. In a therapeutic context, this TCR-peptide-MHC interaction is the primary target of allergen-specific immunotherapy (AIT) [4]. AIT involves the controlled, repeated administration of grass pollen extracts to modify the immune system's response to the allergen [4, 5]. By targeting the TCR signaling pathway under specific conditions, AIT induces peripheral T-cell tolerance, characterized by the expansion of regulatory T cells (Tregs) and a shift from a Th2-dominated response to a Th1 or Treg-dominated one [4, 5]. This modulation results in long-term clinical desensitization and a reduction in the inflammatory symptoms associated with grass pollen exposure [5]. Citations: [1] WHO/IUIS Allergen Nomenclature Database (allergen.org); [2] UniProt Consortium, "T-cell receptor"; [3] Janeway's Immunobiology, 9th Edition; [4] Akdis, C. A., & Akdis, M. (2014), "Mechanisms of allergen-specific immunotherapy," J Allergy Clin Immunol; [5] Durham, S. R., & Shamji, M. H. (2023), "Allergen immunotherapy: past, present and future," Nature Reviews Immunology.
Induction of immune tolerance through allergen-specific immunotherapy (AIT), leading to Th2 cell desensitization and regulatory T cell (Treg) expansion.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Poa compressa-derived peptide–MHC complexes (TCR).